Head to Head Contrast: Cartesian Therapeutics (RNAC) and Its Peers

Cartesian Therapeutics (NASDAQ:RNAC) is one of 1,060 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Cartesian Therapeutics to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, risk, profitability, dividends and earnings.

Profitability

This table compares Cartesian Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-510.72%	N/A	-6.03%
Cartesian Therapeutics Competitors	-3,590.11%	-276.96%	-39.10%

Valuation and Earnings

This table compares Cartesian Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cartesian Therapeutics	$47.94 million	-$219.71 million	-0.34
Cartesian Therapeutics Competitors	$9.59 billion	$147.39 million	-5.41

Cartesian Therapeutics’ peers have higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Cartesian Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics’ peers have a beta of 3.71, suggesting that their average stock price is 271% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Cartesian Therapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	0	2	8	0	2.80
Cartesian Therapeutics Competitors	7830	21280	48937	1242	2.55

Cartesian Therapeutics presently has a consensus target price of $42.86, indicating a potential upside of 139.29%. As a group, “Pharmaceutical preparations” companies have a potential upside of 189.33%. Given Cartesian Therapeutics’ peers higher possible upside, analysts clearly believe Cartesian Therapeutics has less favorable growth aspects than its peers.

Insider & Institutional Ownership

86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 57.9% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Cartesian Therapeutics beats its peers on 8 of the 13 factors compared.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.